Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer

Oliveira, Kelly Cristina da Silva; Bona, Amanda Braga; Silva, Fernanda Jardim Da; Pinheiro, Thayanne Macedo; Alcântara, Diego Di Felipe Ávila; Lamarão, Letícia Martins; Moreira-Nunes, Caroline Aquino; Assumpção, Paulo Pimentel de; Burbano, Rommel Rodrı́guez; Calcagno, Danielle Queiroz

doi:10.21873/anticanres.11579

Cited by 5 publications

(4 citation statements)

References 38 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previously conducted studies, miR‐9 in colon cancer (Cai & Cai, ) and nasopharyngeal carcinoma (J. Lu et al, ) was deregulated with and, therefore, mRNA can be used as a prognostic marker. Moreover, miR‐9 expression was investigated in some cancers such as breast cancer (X. Liu, Luo, Peng, Jiang, & Xu, ), gastric cancer (Oliveira et al, ), CRC (L. Zhu et al, ), and acute myeloid leukemia (AML; Nowek, Sun, Bullinger, et al, , Nowek, Sun, Dijkstra, et al, ). After investigation, its prognosis significance became apparent.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR‐9: From function to therapeutic potential in cancer

Khafaei

Rezaie

Mohammadi

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Malignant neoplasms are regarded as the main cause of death around the world; hence, many research studies were conducted to further perceive molecular mechanisms, treatment, and cancer prognosis. Cancer is known as a major factor for health‐related problems in the world. The main challenges associated with these diseases are prompt diagnosis, disease remission classification and treatment status forecast. Therefore, progressing in such areas by developing new and optimized methods with the help of minimally invasive biological markers such as circular microRNAs (miRNAs) can be considered important. miRNA interactions with target genes have specified their role in development, apoptosis, differentiation, and proliferation and also, confirm direct miRNA function in cancer. Different miRNAs expression levels in various types of malignant neoplasms have been observed to be associated with prognosis of various carcinomas. miR‐9 seems to implement opposite practices in different tissues or under various cancer incidences by influencing different genes. Aberrant miR‐9 levels have been observed in many cancer types. Therefore, we intended to investigate the precise role of miR‐9 in patients with malignant neoplasms. To this end, in this study, we attempted to examine different studies to clarify the overall role of miR‐9 as a prognostic marker in several human tumors. The presented data in this study can help us to find the novel therapeutic avenues for treatment of human cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Lu et al, 2013) was deregulated with and, therefore, mRNA can be used as a prognostic marker. Moreover, miR-9 expression was investigated in some cancers such as breast cancer (X. , gastric cancer (Oliveira et al, 2017), CRC (L. Zhu et al, 2012), and acute myeloid leukemia (AML; . After investigation, its prognosis significance became apparent.…”

mentioning

confidence: 99%

miR‐9: From function to therapeutic potential in cancer

Khafaei

Rezaie

Mohammadi

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…The expression of CDH1 is directly suppressed by miRNAs in GC. For example, the upregulation of miR-9-5p correlates with the downregulation of CDH1 in clinical samples [ 64 ]. In vitro experiments have also shown that miR-9-5p promotes cell migration and invasion by directly targeting this gene [ 65 ].…”

Section: Noncoding Rnas: Classification and Functionsmentioning

confidence: 99%

Competing Endogenous RNA Networks in the Epithelial to Mesenchymal Transition in Diffuse-Type of Gastric Cancer

Landeros

Santoro

Carrasco-Aviño

et al. 2020

Cancers

View full text Add to dashboard Cite

The diffuse-type of gastric cancer (DGC), molecularly associated with epithelial to mesenchymal transition (EMT), is increasing in incidence. Loss of E-cadherin expression is the hallmark of the EMT process and is largely due to the upregulation of the EMT-inducing transcription factors ZEB1/2, Snail, Slug, and Twist1/2. However, ncRNA, such as miRNA and lncRNAs, can also participate in the EMT process through the direct targeting of E-cadherin and other EMT-inducing transcription factors. Additionally, lncRNA can sponge the miRNA pool that targets these transcripts through competing endogenous RNA (ceRNA) networks. In this review, we focus on the role of ncRNA in the direct deregulation of E-cadherin, as well as EMT-inducing transcription factors. Based on the relevance of the ceRNA network hypothesis, and the lack of said networks in EMT, we performed a prediction analysis for all miRNAs and lncRNAs that target E-cadherin, as well as EMT-inducing transcription factors. This analysis resulted in novel predicted ceRNA networks for E-cadherin and EMT-inducing transcription factors (EMT-TFs), as well as the expansion of the molecular basis of the DGC.

show abstract

“…MYC can induce miR-9-3 expression that targets E-cadherin (CDH1), a cellular adhesion protein essential for the cell-cell contact of the gastric epithelium, and promoting tumor cell migration and invasion, leading to EMT in GC [83,127]. The MYC and N-MYC regulation of miR-9 seems to be one of the main pathways to metastasis [128,129].…”

Section: Micrornas Regulate Myc Oncogenic Pathwaysmentioning

confidence: 99%

The Complex Network between MYC Oncogene and microRNAs in Gastric Cancer: An Overview

Anauate

Leal

Calcagno

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Despite the advancements in cancer treatments, gastric cancer is still one of the leading causes of death worldwide. In this context, it is of great interest to discover new and more effective ways of treating this disease. Accumulated evidences have demonstrated the amplification of 8q24.21 region in gastric tumors. Furthermore, this is the region where the widely known MYC oncogene and different microRNAs are located. MYC deregulation is key in tumorigenesis in various types of tissues, once it is associated with cell proliferation, survival, and drug resistance. microRNAs are a class of noncoding RNAs that negatively regulate the protein translation, and which deregulation is related with gastric cancer development. However, little is understood about the interactions between microRNAs and MYC. Here, we overview the MYC role and its relationship with the microRNAs network in gastric cancer aiming to identify potential targets useful to be used in clinic, not only as biomarkers, but also as molecules for development of promising therapies.

show abstract

Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer

Abstract: hsa-miR-9 acts as an oncomiR in HDGC. In addition, we suggest that hsa-miR-9 acts as second event in individuals with HDGC carrying CDH1 gene germinline mutations.

Cited by 5 publications

References 38 publications

miR‐9: From function to therapeutic potential in cancer

miR‐9: From function to therapeutic potential in cancer

Competing Endogenous RNA Networks in the Epithelial to Mesenchymal Transition in Diffuse-Type of Gastric Cancer

The Complex Network between MYC Oncogene and microRNAs in Gastric Cancer: An Overview

Contact Info

Product

Resources

About